# A Study of Regorafenib in Refractory Advanced Gastro-Oesophageal Cancer

> **NCT02773524** · PHASE3 · UNKNOWN · sponsor: **Australasian Gastro-Intestinal Trials Group** · enrollment: 250 (actual)

## Conditions studied

- Gastro-Oesophageal Cancer

## Interventions

- **DRUG:** Regorafenib
- **OTHER:** Placebo

## Key facts

- **NCT ID:** NCT02773524
- **Lead sponsor:** Australasian Gastro-Intestinal Trials Group
- **Sponsor class:** NETWORK
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** UNKNOWN
- **Start date:** 2016-11
- **Primary completion:** 2022-01
- **Final completion:** 2022-12
- **Target enrollment:** 250 (ACTUAL)
- **Last updated:** 2022-01-13

## Collaborators

- [object Object]
- [object Object]
- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT02773524

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT02773524, "A Study of Regorafenib in Refractory Advanced Gastro-Oesophageal Cancer". Retrieved via AI Analytics 2026-06-02 from https://api.ai-analytics.org/clinical/NCT02773524. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*